Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
[Display omitted] Sustained proliferative capacity is a hallmark of cancer. In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate critical checkpoints. CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essent...
Gespeichert in:
| Veröffentlicht in: | Bioorganic & medicinal chemistry letters 2015-09, Vol.25 (17), p.3420-3435 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3435 |
|---|---|
| container_issue | 17 |
| container_start_page | 3420 |
| container_title | Bioorganic & medicinal chemistry letters |
| container_volume | 25 |
| creator | Sánchez-Martínez, Concepción Gelbert, Lawrence M. Lallena, María José de Dios, Alfonso |
| description | [Display omitted]
Sustained proliferative capacity is a hallmark of cancer. In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate critical checkpoints. CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point. This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compounds under clinical evaluation. Chemical structures, structure activity relationships, and relevant preclinical properties will be described. |
| doi_str_mv | 10.1016/j.bmcl.2015.05.100 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1701340648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960894X15005843</els_id><sourcerecordid>1701340648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-a6199e4537c2549940d4ad495c978acfba61abe1daa5a0b36ac13231f046ef0a3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbK3-AQ-SYz0kzia7mwZ6kfiJBS8K3pbN7kS3pkndTYT-e7e0ehQGBobnfWEeQs4pJBSouFom1Uo3SQqUJ8DDDQ7ImDLB4owBPyRjKATEs4K9jciJ90sAyoCxYzJKBaWc53RM5uVGN7aNDK6xNdj20adtlcdoWt48XUa2_bCV7TvnIxWm7a1WrUYXGTe8-1NyVKvG49l-T8jr3e1L-RAvnu8fy-tFrFkq-lgJWhTIeJbrlLOiYGCYMqzgushnStdVAFSF1CjFFVSZUJpmaUZrYAJrUNmETHe9a9d9Deh7ubJeY9OoFrvBS5oDDS8LNgtoukO167x3WMu1syvlNpKC3FqTS7m1JrfWJPBwgxC62PcP1QrNX-RXUwDmOwDDl98WnfTaYhBhrEPdS9PZ__p_APIsfKU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1701340648</pqid></control><display><type>article</type><title>Cyclin dependent kinase (CDK) inhibitors as anticancer drugs</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Sánchez-Martínez, Concepción ; Gelbert, Lawrence M. ; Lallena, María José ; de Dios, Alfonso</creator><creatorcontrib>Sánchez-Martínez, Concepción ; Gelbert, Lawrence M. ; Lallena, María José ; de Dios, Alfonso</creatorcontrib><description>[Display omitted]
Sustained proliferative capacity is a hallmark of cancer. In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate critical checkpoints. CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point. This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compounds under clinical evaluation. Chemical structures, structure activity relationships, and relevant preclinical properties will be described.</description><identifier>ISSN: 0960-894X</identifier><identifier>EISSN: 1464-3405</identifier><identifier>DOI: 10.1016/j.bmcl.2015.05.100</identifier><identifier>PMID: 26115571</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; CDK inhibitors ; Cell Cycle ; Cyclin-Dependent Kinase Inhibitor Proteins - metabolism ; Humans ; Neoplasms - drug therapy</subject><ispartof>Bioorganic & medicinal chemistry letters, 2015-09, Vol.25 (17), p.3420-3435</ispartof><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-a6199e4537c2549940d4ad495c978acfba61abe1daa5a0b36ac13231f046ef0a3</citedby><cites>FETCH-LOGICAL-c426t-a6199e4537c2549940d4ad495c978acfba61abe1daa5a0b36ac13231f046ef0a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bmcl.2015.05.100$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26115571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sánchez-Martínez, Concepción</creatorcontrib><creatorcontrib>Gelbert, Lawrence M.</creatorcontrib><creatorcontrib>Lallena, María José</creatorcontrib><creatorcontrib>de Dios, Alfonso</creatorcontrib><title>Cyclin dependent kinase (CDK) inhibitors as anticancer drugs</title><title>Bioorganic & medicinal chemistry letters</title><addtitle>Bioorg Med Chem Lett</addtitle><description>[Display omitted]
Sustained proliferative capacity is a hallmark of cancer. In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate critical checkpoints. CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point. This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compounds under clinical evaluation. Chemical structures, structure activity relationships, and relevant preclinical properties will be described.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>CDK inhibitors</subject><subject>Cell Cycle</subject><subject>Cyclin-Dependent Kinase Inhibitor Proteins - metabolism</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><issn>0960-894X</issn><issn>1464-3405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1Lw0AQhhdRbK3-AQ-SYz0kzia7mwZ6kfiJBS8K3pbN7kS3pkndTYT-e7e0ehQGBobnfWEeQs4pJBSouFom1Uo3SQqUJ8DDDQ7ImDLB4owBPyRjKATEs4K9jciJ90sAyoCxYzJKBaWc53RM5uVGN7aNDK6xNdj20adtlcdoWt48XUa2_bCV7TvnIxWm7a1WrUYXGTe8-1NyVKvG49l-T8jr3e1L-RAvnu8fy-tFrFkq-lgJWhTIeJbrlLOiYGCYMqzgushnStdVAFSF1CjFFVSZUJpmaUZrYAJrUNmETHe9a9d9Deh7ubJeY9OoFrvBS5oDDS8LNgtoukO167x3WMu1syvlNpKC3FqTS7m1JrfWJPBwgxC62PcP1QrNX-RXUwDmOwDDl98WnfTaYhBhrEPdS9PZ__p_APIsfKU</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Sánchez-Martínez, Concepción</creator><creator>Gelbert, Lawrence M.</creator><creator>Lallena, María José</creator><creator>de Dios, Alfonso</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Cyclin dependent kinase (CDK) inhibitors as anticancer drugs</title><author>Sánchez-Martínez, Concepción ; Gelbert, Lawrence M. ; Lallena, María José ; de Dios, Alfonso</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-a6199e4537c2549940d4ad495c978acfba61abe1daa5a0b36ac13231f046ef0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>CDK inhibitors</topic><topic>Cell Cycle</topic><topic>Cyclin-Dependent Kinase Inhibitor Proteins - metabolism</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sánchez-Martínez, Concepción</creatorcontrib><creatorcontrib>Gelbert, Lawrence M.</creatorcontrib><creatorcontrib>Lallena, María José</creatorcontrib><creatorcontrib>de Dios, Alfonso</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sánchez-Martínez, Concepción</au><au>Gelbert, Lawrence M.</au><au>Lallena, María José</au><au>de Dios, Alfonso</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cyclin dependent kinase (CDK) inhibitors as anticancer drugs</atitle><jtitle>Bioorganic & medicinal chemistry letters</jtitle><addtitle>Bioorg Med Chem Lett</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>25</volume><issue>17</issue><spage>3420</spage><epage>3435</epage><pages>3420-3435</pages><issn>0960-894X</issn><eissn>1464-3405</eissn><abstract>[Display omitted]
Sustained proliferative capacity is a hallmark of cancer. In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate critical checkpoints. CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point. This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compounds under clinical evaluation. Chemical structures, structure activity relationships, and relevant preclinical properties will be described.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26115571</pmid><doi>10.1016/j.bmcl.2015.05.100</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-894X |
| ispartof | Bioorganic & medicinal chemistry letters, 2015-09, Vol.25 (17), p.3420-3435 |
| issn | 0960-894X 1464-3405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1701340648 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use CDK inhibitors Cell Cycle Cyclin-Dependent Kinase Inhibitor Proteins - metabolism Humans Neoplasms - drug therapy |
| title | Cyclin dependent kinase (CDK) inhibitors as anticancer drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A50%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cyclin%20dependent%20kinase%20(CDK)%20inhibitors%20as%20anticancer%20drugs&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry%20letters&rft.au=S%C3%A1nchez-Mart%C3%ADnez,%20Concepci%C3%B3n&rft.date=2015-09-01&rft.volume=25&rft.issue=17&rft.spage=3420&rft.epage=3435&rft.pages=3420-3435&rft.issn=0960-894X&rft.eissn=1464-3405&rft_id=info:doi/10.1016/j.bmcl.2015.05.100&rft_dat=%3Cproquest_cross%3E1701340648%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1701340648&rft_id=info:pmid/26115571&rft_els_id=S0960894X15005843&rfr_iscdi=true |